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Abstract 
 
Background 
Shared decision-making (SDM) aims to empower patients to take an active role in their treatment choices, 
supported by clinicians and patient decision aids (PDAs). The purpose of this study is to explore barriers 
and possible facilitators to SDM and a PDA in the prostate cancer trajectory. In the process we identify 
possible actions that organizations and individuals can take to support implementation in practice.  
Methods 
We use the Ottawa Model of Research Use as a framework to determine the barriers and facilitators to 
SDM and PDAs from the perspective of clinicians. Semi-structured interviews were conducted with urol-
ogists (n=4), radiation oncologists (n=3), and oncology nurses (n=2), focusing on the current decision-
making process experienced by these stakeholders. Questions included their attitudes towards SDM and 
PDAs, barriers to implementation and possible strategies to overcome them. 
Results 
Time pressure and patient characteristics were cited as major barriers by 55% of the clinicians we inter-
viewed. Structural factors such as external quotas for certain treatment procedures were also considered 
as barriers by 44% of the clinicians. Facilitating factors involved organizational changes to embed PDAs in 
the treatment trajectory, training in using PDAs as a tool for SDM, and clinician motivation by disseminat-
ing positive clinical outcomes. Our findings also suggest a role for external stakeholders such as healthcare 
insurers in creating economic incentives to facilitate implementation. 
 Conclusion 
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Our findings highlight the importance of a multi-faceted implementation strategy to support SDM. While 
clinician motivation and patient activation are essential, structural/economic barriers may hamper imple-
mentation. Action must also be taken at the administrative and policy levels to foster a collaborative en-
vironment for SDM and, in the process, for PDAs.  
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Background 
Shared decision-making (SDM) is the process of collaboration between clinicians and patients to come to 
a treatment decision based on the best available clinical information and the patient’s personal prefer-
ences (1). Making treatment choices in oncology is becoming increasingly complex; patients must not only 
absorb a large amount of clinical information but also weigh multiple treatment options in terms of ben-
efits and harms while confronting the emotional and psychological aspects of their disease (2). Lack of 
awareness about different treatment options can result in patients making choices that are not aligned 
with their values (3). Such decisions often lead to decisional regret (4, 5). Patient decision aids (PDAs) are 
tools that help inform patients about their treatment options and in some cases help them clarify their 
values. PDAs are often used to facilitate SDM. A growing body of evidence suggests that patients who use 
PDAs are better informed about their condition and preferences, have better risk perceptions, and have 
lower decisional conflict compared to patients who receive usual care (3).  
In the Netherlands, policymakers at various levels (government, healthcare insurers, and patient advocacy 
groups) are actively facilitating an increased role for patients in the management of their own health 
through initiatives such as the Dutch Decision Aids Implementation Program (D-DAP) (6). These initiatives 
are yet to translate into increased patient involvement on the whole and challenges remain in integrating 
PDAs in clinical practice (7). These include poor design of the tools themselves and a lack of usability (8). 
Clinicians may lack awareness of PDAs (9) or may believe that they are of limited value in practice (10). 
Integration into existing workflows presents a structural barrier (11), along with an ongoing need to keep 
PDAs up to date in order to keep pace with the rapidly changing landscape of oncological research. As yet, 
there has been little discussion on what organizational changes can be made to support the use of PDAs 
in clinical practice. 
Furthermore, research on implementation tends to conflate SDM and PDAs (12). For instance, a system-
atic review on barriers and facilitators to SDM defines SDM both as the process of clinician-patient en-
gagement as well as an intervention such as a PDA (13). However, providing a PDA does not guarantee 
that SDM will take place, and a PDA implemented in an environment that is not conducive to SDM may 
not show an improvement in outcomes (14). Therefore, when introducing a PDA into a clinical context it 
is worthwhile to consider the barriers and facilitators not only to the tool itself but also to SDM in the 
environment the tool will be implemented in. With this knowledge it may be possible to derive an imple-
mentation strategy that uses the PDA to support SDM. 
This study was conducted as a precursor to implementing a web-based prostate cancer PDA developed at 
our clinic (15). We began with the premise that PDAs may be a useful tool for SDM to the extent that SDM 
can be successfully implemented in the clinical environment. Any implementation strategy should there-
fore consider both the barriers and facilitators to SDM and the resulting implications for the PDA. We 
explore these factors in parallel from the clinician perspective. 
Methods 
We used the Ottawa model of research use (OMRU) as a framework for our data collection (16). The 
OMRU outlines three factors that must be monitored when implementing a new health intervention (see 
Fig. 1): the intervention itself (in this context, the PDA), the readiness of the potential adopters (practi-
tioners/patients), and factors in the practice environment, such as culture, workflows, and resources, that 
may be barriers or supports.  
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Figure 1: Ottawa model of research use (17)  
These factors were studied by interviewing nine clinicians specialized in prostate cancer (four urologists, 
three radiation oncologists, and two oncology nurses) within our clinic in a semi-structured interview for-
mat. The clinicians ranged in experience commensurate with their age. Characteristics of the participants 
are displayed in Fig. 2. Interview questions were based on the following components of the OMRU: current 
treatment process, awareness of SDM principles, attitudes towards SDM and PDAs, beliefs about exter-
nal/organizational factors that might inhibit the application of SDM and use of PDAs, and lastly actions 
that can be taken within the organization to foster PDA uptake. Interview questions covered their percep-
tions of SDM and PDAs in general as well as of the prostate cancer PDA developed previously. Participants 
were sent a link to the PDA two weeks before the interview to familiarize themselves with it.  
Interviews lasted between 30 to 60 minutes and were taped using a voice recorder. The recordings were 
then transcribed fully and emailed back to the participants for their review and approval. After approval, 
each transcript was analyzed by means of open coding in which text fragments were assigned codes sum-
marizing their meaning. Subsequently, to identify relationships between the open codes, we performed 
axial coding by grouping the open codes according to their underlying themes. To improve the validity of 
the results a sample of the interviews were coded separately by two different researchers and compared 
to reconcile any differences. 
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Figure 2: Participant demographics 
 
Results 
Our analysis resulted in a list of barriers and facilitators to SDM at the individual, organizational and ex-
ternal level, as well as attributes of PDAs that could hinder or support to their implementation. The full 
list is summarized in Table 1. 
Barriers and facilitators to SDM 
Potential adopters 
Our results revealed an overall positive attitude towards SDM among clinicians, with most expressing that 
following a patient’s preference is ideal and that SDM should be more prevalent in clinical practice than 
it is currently. They mentioned several factors that may hinder SDM in practice, namely time pressure/ef-
ficiency, the nature of SDM itself, patient characteristics, and clinician characteristics. 
More than half (five out of nine) clinicians mentioned time pressure as the biggest barrier to SDM. Some 
perceived it to be an inefficient process to engage in dialogue with the patient about his preferences. Two 
clinicians noted that it is easier to decide the treatment option themselves based on their clinical experi-
ence. Time constraints were a more significant barrier for urologists, with radiation oncologists reporting 
that they have enough time for the patients. Three urologists mentioned that their consultations average 
10-15 minutes. Radiation oncologists said that they have around 45-60 minutes to discuss treatment de-
tails, and one nurse reported having 30-45 minutes for each patient and more time if necessary. 
’I think that [SDM] is much less efficient, it is very time-consuming. [...] It is far easier to just 
say “This is [the best option]”.’ (Radiation oncologist 2) 
Five clinician expressed doubts about SDM as a paradigm, highlighting the burden that SDM may place on 
the patient by making him responsible for treatment choices. Patients can get overwhelmed by the vol-
ume of clinical information needed to make treatment decisions. They may also lack complete or balanced 
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information, which makes it more difficult for them to make an informed choice. The need to make a 
treatment choice may also induce stress and confusion.  
‘[SDM] asks a lot of the patient. And that also means where things go wrong, which hap-
pens sometimes, of course, you also have those people who have been irradiated and who 
[regret it]. They say “I should have chosen operation.” […] We now place the choice with 
the patient and with it the responsibility more or less is on him.’ (Urologist 3) 
Finally, certain clinician characteristics were thought to influence the scope for SDM. Expertise was one 
characteristic; clinicians are more knowledgeable about their own specialization and may have less expe-
rience with other treatments. For instance, urologists are able to provide information on surgery in greater 
detail than on radiotherapy in which they have less direct expertise. However, they are the lead clinicians 
overseeing most of the treatment trajectory and are responsible for having the decisional talk with the 
patient. Four clinicians found this a significant barrier to SDM because incomplete information may pre-
vent the patient from making a balanced choice. Another characteristic mentioned by one participant was 
the clinician’s age, with the perception being that younger clinicians are more open to SDM while it re-
quires a mentality change for their more senior peers.  
‘The age-old discussion is that people preach to the converted. [...] I would say the patient 
has to have surgery, a radiation oncologist would say he has to have radiotherapy.’ (Urolo-
gist 1) 
The biggest facilitator at the individual level was the motivation of the clinician leading the treatment 
process (in this case, the urologist). Clinicians reported that they would be more open to SDM if they were 
convinced that it leads to better patient outcomes and does not lengthen the decision-making process. 
‘[They] must also see the benefit, that patients are more satisfied, that they get more in-
sight into their disease, that they ultimately have a better quality of life. The person imple-
menting or actually offering it to patients must be convinced of that.’ (Radiation oncologist 
1) 
Practice environment 
Participants cited two main barriers in the clinic environment: patient characteristics and structural fac-
tors. Patient characteristics included the patient’s age, health literacy and willingness to participate in 
SDM. Three clinicians mentioned that the advanced age of the typical prostate cancer patient makes it 
challenging to engage the patient in the decision-making process. Furthermore, many older patients are 
used to a paternalistic model of decision-making in which the clinician advises the patient on the best 
treatment. The wide variety in patient backgrounds, some being more educated than others and better 
able to understand clinical information, presented another challenge according to one clinician. Finally, 
some patients are willing to take an active role while others prefer the clinician to take the lead, and even 
when decisions are made jointly, a considerable portion of patients are highly influenced by the clinician’s 
opinion.  
‘You have to imagine that there are different [types] of patients. From highly educated to 
minimally educated and that involves a totally different manner of communication.’ (Urolo-
gist 1) 
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‘The patients, particularly the elderly patients [...], are more used to a paternalistic model, 
they believe [...] that the doctor knows what is best for them.’ (Radiation oncologist 2) 
Four clinicians cited structural factors that may impede SDM. First, in the current treatment trajectory the 
urologist is the first point of contact for the patient and oversees most of the process, from initial diagnosis 
to the final decision. The urologist carries out the decisional talk with the patient and presents all relevant 
treatment options. If radiotherapy is chosen then the patient is referred to the radiation oncologist for 
further treatment, however many patients tend to choose surgery. Second, government-set quotas on 
the required number of surgeries to be performed by hospitals may incentivize treatment choices to be 
steered in that direction.   
‘There are guidelines in the Netherlands on prostatectomy. To be able to do such a prostate 
surgery you must achieve a minimum number per year.’ (Radiation oncologist 3) 
‘We also have to get a certain number of operations and that is also from the government.’ 
(Urologist 4) 
Clinicians suggested several actions that would facilitate SDM implementation, beginning with making it 
an organizational priority. Creating the time and space for it, both literally in terms of more contact time 
with the patient and physical set-ups such as joint consultations, and logistically such as through training 
and addressing external factors such as treatment quotas. Clinicians suggested training to acquaint their 
peers with the principles of SDM and how to elicit participation from the patient. Some clinicians valued 
an e-Learning course about the basics of practicing SDM, others suggested face-to-face demonstrations 
so that clinicians could inform and educate their patients more effectively. 
Joint consultations were proposed to reduce information asymmetry between the different specializa-
tions. If radiotherapists and urologists were to participate in consultations together with the patient this 
could improve the decision-making process by giving all parties a more balanced perspective of the op-
tions available and patient’s preferences. Despite the potential benefits, most clinicians highlighted the 
organizational challenges this level of care coordination may present.   
‘An online [course] is the easiest as you can follow it in your own time […] the so-called e-
Learning.’ (Radiation oncologist 3) 
’It would be great to have an oncology center for example, where you could discuss every-
thing with another specialist [...] but that is also difficult.’ (Urologist 4) 
‘The [hospital] must be ready [for] the extra logistical challenges […] to have two doctors in 
place of one, and preferably at the same time or at the same clinic.’ (Radiation oncologist 
3) 
Barriers and facilitators to PDAs 
In light of existing time pressures, clinicians said they would be less likely to use the PDA if it was too 
complicated to understand or apply. This included factors such as the time taken to navigate through the 
PDA, fill in information such as patient details, and discuss the outputs in the consultation with the patient. 
Another potential barrier was accessibility in the case of a web-based PDA; patients, particularly the el-
derly, may not be familiar enough with PCs/tablets to use the PDA.  
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‘If we have to log in […] it will cost us a lot of time and energy. It should therefore remain 
simple.’ (Urologist 4) 
‘If the decision aid is too difficult or too complicated then it is not usable. So you have to 
adjust it to the mainstream population of course." (Radiation oncologist 1) 
‘So people have to have access to a computer, access to the internet. If there are people 
who really don't understand or who can't read or who can't use a computer or don't have 
internet access, yes then it is difficult.’ (Urologist 2) 
Numerous facilitators were proposed, both on the PDA-level as well as in the development process. Three 
radiation oncologists and two urologists cited the critical role of the urologist in implementing a PDA as 
urologists are the first point of contact for the patient after referral and oversee a large part of the treat-
ment trajectory. Motivating the urologist was seen as a stimulating factor, as the clinician who offers the 
PDA must be convinced of its added value. This can be enhanced by showing positive results associated 
with the use of PDAs, for example that patients may face less decisional regret and accept the side effects 
and complications more readily if he has opted for treatment himself.  
At a structural level, embedding the PDA in the patient pathway in a standardized manner was seen as an 
ideal way to make the informing process more efficient. Oncology nurses were named as the most effec-
tive channel through which the patients could be introduced to the PDA and guided through the process 
of applying it, since they were regarded as more approachable for the patients. Involving additional per-
sonnel in this manner was thought to save time during consultations. The present role of oncology nurses 
is to provide the patient with practical and logistical information about their treatment options. These 
include the procedures for the different treatments and the implications in terms of hospital visits and so 
forth. We did not find evidence that nurses engage the patient in actual deliberation or decision-making; 
this function appears to be performed solely by the clinicians. Finally, two clinicians mentioned compen-
sation for the use of PDA as a facilitating factor. 
‘All the diagnostics and the workup up to and including the diagnosis, plus discussing the 
tumor board decision are all with the urologist himself. So he is the key player; if he does 
not use it or does not recommend it, nothing happens.’ (Radiation oncologist 3) 
‘[Implementation] is only possible if all clinicians are obliged to use [the PDA]. But that will 
never happen of course. Unless instead, you get compensation from the health insurance 
company.’ (Radiation oncologist 1)  
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Table 1: Summary of barriers and facilitators to SDM and PDA implementation from clinicians’ perspective and the number of 
clinicians who mentioned each factor 
Level Barrier N Facilitator N 
Potential adopters    
Attitudes towards SDM • Burden on patient 5 • Better patient outcomes 3 
 • Takes too much time 5 • Clinician motivation 3 
Knowledge/skill • Expertise in specialization 3   
Practice environment     
Patient characteristics • Age 3   
 • Health literacy 3   
 • Willingness to participate 2   
Cultural/social • Paternalistic attitudes 2   
Structural • Not enough time 4 • Training  5  
 • Volume quotas 4 • Organizational priority 4 
   • More contact time with pa-
tient 
2 
Economic   • Compensation 2 
PDA    
Development process   • Clinician involvement 3 
Attributes • Requires computer skills  3 • Balanced information  
 • Time-consuming  2 • Embedded in workflow 3 
   • Biased information 2 • Personalized 2 
   • Complicated 2 • Interactive 2 
 
Discussion 
Implementing a new health intervention involves action on multiple levels, centering on the intervention 
itself, the people who will use it, and the environment in which it will be introduced. In this study, we 
interviewed clinicians to understand their perspective on the factors that can hinder or support SDM im-
plementation, and what actions may support the use of a PDA. Overall, our findings corroborate existing 
evidence that time pressure and patient characteristics are perceived as the biggest barriers to SDM (13). 
Our study also sheds light on barriers that have received little attention in the literature, such as certain 
structural and economic incentives that may affect PDA uptake and the scope for SDM. In analyzing our 
findings in the context of existing literature, we propose nine recommendations for PDA implementation. 
Our list is by no means exhaustive but address some of the more prominent issues in SDM implementation 
and suggests actions that may increase the likelihood of implementation success.  
Recommendation 1: Make SDM and PDA implementation an organizational priority 
Current literature on SDM tends to focus on the interaction between clinician and patient, however 
organizational factors can heavily influence the implementation of PDAs and other health interven-
tions. These factors include, among others, the organizational culture, available resources, and clinical 
workflows (18). Our participants emphasized the importance of making SDM initiatives an organiza-
tional priority through strategies such as coordination across specializations (e.g. joint consultations). 
This theme is echoed in several studies, namely that actions taken on multiple levels are more effective 
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than those that target a single level (19, 20). Strong leadership plays a key role in coordinating imple-
mentation efforts across the organization and improving quality of care (21). Simultaneously, empow-
ering clinicians by giving them a degree of autonomy in SDM agendas may make implementation ef-
forts more effective (22). Examples may include inviting clinician participation and feedback in goal 
setting and developing SDM training activities.  
Recommendation 2: Create ownership 
Clinician motivation was considered one of the biggest facilitators by our study participants. This is also 
the top-most factor mentioned in a systematic review of barriers and facilitators (13). Prior studies 
have shown that uptake of innovations in general, and PDAs specifically, is enhanced when end users 
are involved throughout the development process (23-27).  Involving clinicians in PDA development 
and evaluation may help create trust and ownership in the PDA and make it more likely that these 
clinicians will use the PDA in their practice. If the PDA is to be implemented in several clinics or geo-
graphical areas, ownership could be created by providing customization options (28), such as the pos-
sibility for other clinics to add their own logo or informational videos made with their own clinicians to 
the PDA.  
Recommendation 3: Make the PDA interactive and/or personalized  
SDM is, by definition, an interactive process between clinician and patient. The former provides clinical 
information and the latter shares their preferences and what matters to them so that both can make 
a treatment decision together. Eliciting patient preferences was cited as a challenge for clinicians in 
our study and other studies (29). In particular, elderly cancer patients who are used to a paternalistic 
decision-making process are more prone to following the clinician’s advice. An interactive and/or per-
sonalized PDA may prompt patients to engage in the SDM process more actively and provide a platform 
for sharing personal preferences and values. One solution is to include an interactive element in the 
PDA, such as filling in values clarification questions which stimulate the patient to consider what mat-
ters to him. Patients may not always know their preferences beforehand, and the act of weighing treat-
ment options and discussing the possibilities with a clinician can help preferences emerge (30). These 
results can then be summarized and presented back to the patient for further reflection and taken into 
the consultation as an input for the decisional talk.  
Recommendation 4: Bring the PDA into the consultation 
Many PDAs are given to patients as supplementary material to be used at home (8), with the benefit 
that the patient can go over the material at their own pace. One drawback is that it is difficult to de-
termine whether the patient used the PDA, whether it was used correctly, and to what extent it had 
an impact on the decision process. There is evidence that simplified PDAs designed for use in the con-
sultation itself stimulate dialogue and patient engagement (31). Developers could consider a combina-
tion of a ‘regular’ PDA for home use combined with a simpler version that clinicians can use in consul-
tations. Alternatively, the regular PDA can be incorporated into the consultation in different formats. 
An electronic PDA could be connected to the hospital’s electronic health record (EHR) system so that 
patient preferences or other relevant details are accessible to clinicians. Pure paper-based PDAs being 
used in consultations as part of an SDM process have also shown promising results (32). Randomized 
controlled trials show little difference in electronic vs. paper PDAs in terms of patient knowledge about 
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prostate cancer, patient participation in decision-making, and decisional conflict, but find that PDAs 
combined with an SDM talk are more effective than PDAs given as a stand-alone tool (33). 
Recommendation 5: Obtain a certification mark 
Reliability and balanced information provided by the PDA was a priority for the clinicians we inter-
viewed. As PDAs can potentially influence treatment choices there needs to be a way to maintain pa-
tient safety (34). Current criteria such as the International Patient Decision Aid Standards (IPDAS) out-
line a step-by-step process to guide PDA development to maximize quality, reliability, and user ac-
ceptance (35). This process is prescriptive however and may not necessarily guarantee a generally ac-
cepted measure of quality. Certification such as CE marking may support implementation by ensuring 
that the PDA meets well-established quality standards. This provides incentives for clinicians, hospital 
administrators, patients and insurers to use them in practice (36).  
Recommendation 6: Engage additional staff in PDA delivery 
With time constraints being a prominent barrier to SDM among our clinicians and other studies (13), 
there may be a role for additional personnel in the delivery and use of the PDA. Urologists interviewed 
for this study considered oncology nurses to be the ideal channel through which to offer the PDA to 
patients. They felt that nurses are better equipped to guide patients through the PDA if required and 
answer any questions. Our interviews with nurses, however, revealed that at present they are not 
trained to help patients make treatment decisions. Findings from other countries also show that nurses 
are not trained to specifically engage in SDM or introduce PDAs (37-39). Research highlights the im-
portance of nurses receiving such training (40), particularly since SDM is not only relevant to major 
treatment decisions but also small decisions along the treatment trajectory where nurse support is 
invaluable (41).  
Recommendation 7: Training 
Clinicians who receive training in SDM report greater confidence in their abilities and increased positive 
attitudes towards SDM (42). PDAs are most effective when they are combined with an SDM conversa-
tion than when given to the patient as a stand-alone tool (33). Therefore, clinicians who are skilled in 
SDM are in a better position to deploy and use PDAs as part of their practice. While there is no con-
sensus in the literature regarding the specific core competencies clinicians need in order to effectively 
involve patients in decision-making, prior findings highlight the importance of developing relational 
competencies (creating quality interactions between clinicians and patients) and risk communication 
competencies (helping patients understand treatment options, risks, and so on.) (43)  
Recommendation 8: Create appropriate incentives 
External incentives such as volume quotas for certain treatments pose another challenge to PDA im-
plementation that has not been adequately addressed in the literature. Patients who are better in-
formed about all relevant aspects of their disease and treatment tend towards choosing more con-
servative treatments (3). Dutch healthcare insurers are becoming more knowledgeable about SDM and 
supporting methods to ensure that patients receive treatments tailored to their profile and prefer-
ences (44). Insurers can stimulate patients and clinicians to take a more collaborative role in treatment 
decisions, for instance by paying clinicians for the use of PDAs or making their use a prerequisite for 
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reimbursing certain procedures. Inclusion of a reimbursement code for the PDA can help standardize 
the process and speed up its usage, particularly since insurers see evidence of PDA use as one way to 
make the SDM process more visible and are heavily influencing hospitals to implement them (45). 
Moving from a volume-based to value-based healthcare model requires foremost collaboration be-
tween clinicians, hospital administrators, patients, patient advocacy groups to define appropriate out-
come metrics and develop strategies to measure, analyze and disseminate the findings to continuously 
improve care quality (46). 
Recommendation 9:  Measurement and evaluation 
Our clinicians believed that evidence of improved outcomes would provide a greater impetus to use 
and recommend PDAs to patients and take part in SDM. Currently, there are a variety of validated 
instruments to measure the effects of SDM along different dimensions. These include the OPTION scale 
measuring the level of SDM itself (47), the SDM-Q-9 measuring patient and clinician participation in 
the SDM process (48), the decisional conflict scale (49), and patients’ post-treatment decision regret 
(50). In addition, routinely collected patient-reported outcomes (PROMs) may be useful in evaluating 
SDM initiatives or as a basis for values clarification (51). Care must be taken however when interpreting 
SDM outcome measures. In particular, what constitutes a ‘good’ clinical decision is open to debate (52) 
and outcomes may not be the most reliable indicator of decision quality. For instance, a patient’s eval-
uation of their decision may change over time as long-term consequences become more apparent. 
More research is needed on methods to evaluate the decision-making process and its effects.   
To our knowledge this is the first study that explores SDM and PDA implementation in parallel. We regard 
PDAs as a support to SDM and explore their implementation as a synergistic process. In taking this broader 
perspective, our study reveals factors that may affect PDA implementation that are not directly related to 
the PDA itself, for instance volume quotas. Another contribution of our work is the focus on clinician sug-
gestions for implementation; buy-in from clinicians is crucial when introducing any innovation, and it is 
reasonable to assume that clinicians will be more open to strategies originating from their peers. 
Despite our best efforts to remain objective, our study may suffer from bias associated with qualitative 
research, namely interpretation bias and sampling bias. To the extent possible we have tried to avoid the 
former by having participants review their interview transcripts and by coding in parallel with two re-
searchers. Our sample size is small and limited to one clinic and therefore care should be taken when 
extrapolating our results to different contexts. Nevertheless, our findings largely correspond with existing 
literature, indicating that some level of generalizability is maintained. Also, although the context of our 
study was prostate cancer management, our recommendations may be generalizable to other preference-
sensitive contexts in which a choice needs to be made between two or more comparable treatment op-
tions. Future work might consider the role of oncology nurses in SDM/PDA implementation, as this group 
was underrepresented in our study. It may also be valuable to conduct a similar study from the patient 
perspective. Future research might also explore how the activities and communication methods of patient 
organizations can be leveraged in SDM and PDA implementation, as well as those of healthcare insurers. 
 
Conclusion 
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PDAs are a useful supporting tool for SDM by helping patients clarify their preferences and engage in the 
decision-making process. Implementation is a multifaceted process requiring action on several levels. Bar-
riers and facilitators exist at the individual patient-clinician level, at the organizational level, and in the 
external environment. A PDA implementation strategy should include an assessment of the extent to 
which the implementation environment is conducive to SDM. With this in mind, coordinated actions can 
be taken at the individual, administrative, and policy level to support patient engagement.   
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List of abbreviations 
 
PDA – Patient decision aid 
SDM – Shared decision-making 
IPDAS – International Patient Decision Aid Standards 
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